Organic compositions to treat EPAS1-related diseases
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
1. A composition comprising an RNAi agent for inhibiting expression of an EPAS1 gene comprising a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:61 differing by 0 or 1 nucleotides, and the sense strand comprises the nucleotide sequence of SEQ ID NO:42 differing by 0 or 1 nucleotides, and wherein the RNAi agent comprises at least one 2′-modified nucleotide on the antisense strand.
2. The composition of claim 1 , wherein the composition further comprises a second RNAi agent that inhibits the EPAS1 gene.
3. The composition of claim 1 , wherein the antisense strand is about 30 or fewer nucleotides in length.
4. The composition of claim 1 , wherein the sense strand and the antisense strand form a duplex region about 15 to about 30 nucleotide pairs in length.
5. The composition of claim 1 , wherein the antisense strand and the sense strand are both about 19 to about 23 nucleotides in length.
6. The composition of claim 1 , wherein the RNAi agent comprises a modified sugar backbone, including a phosphorothioate linkage.
7. The composition of claim 1 , wherein the RNAi agent comprises a 2′-modification selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O- methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-ODMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-ODMAEOE), and 2′-O—N-methylacetamido (2′-O—NMA).
8. The composition of claim 1 , wherein the RNAi agent comprises a blunt end.
9. The composition of claim 1 , wherein the RNAi agent comprises an overhang having 1 to 4 unpaired nucleotides.
10. The composition of claim 1 , wherein the RNAi agent is ligated to one or more diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecogenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and transferrin.
11. A method of inhibiting the expression of EPAS1 in an individual, comprising the step of administering to the individual a therapeutically effective amount of a composition comprising an RNAi agent of claim 1 .
12. The method of claim 11 , wherein the individual is afflicted with or susceptible to an EPAS1-related disease.
13. The method of claim 11 , wherein the EPAS1-related disease is cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, or rheumatoid arthritis.
14. The method of claim 11 , wherein the EPAS1-related disease is cancer.
15. The method of claim 11 , wherein the method further comprises the step of administering an additional disease treatment.
16. The method of claim 11 , wherein the composition further comprises a second RNAi agent to EPAS1.
17. The composition of claim 1 , wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO: 61 and the sense strand comprises the nucleotides sequence of SEQ ID NO: 42.
18. The composition of claim 1 , wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO: 99 and the sense strand comprises the nucleotides sequence of SEQ ID NO: 80.
19. The composition of claim 1 , wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO: 129 and the sense strand comprises the nucleotides sequence of SEQ ID NO: 148.